Effect of l-deprenyl and gliclazide on oxidant stress/antioxidant status and DNA damage in a diabetic rat model

Endocrine Research

Volumn 31, Issue 3, 2005, Pages 199-212

  Alper, Gulinnaz ^a   Irer, Seda ^a   Duman, Erdal ^a   Caglayan, Osman ^b   Yilmaz, Candeger ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

1 Deprenyl; 8 OHdG; Antioxidant status; Diabetes mellitus; Gliclazide; Oxidant stress

Indexed keywords

CATALASE; GLICLAZIDE; SELEGILINE; SUPEROXIDE DISMUTASE; 8 HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDIABETIC AGENT; ANTIOXIDANT; DEOXYGUANOSINE; DRUG DERIVATIVE; MALONALDEHYDE; MONOAMINE OXIDASE INHIBITOR; OXIDIZING AGENT; RETINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DNA DAMAGE; ERYTHROCYTE; LIVER; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; AGING; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; LIPID PEROXIDATION; METABOLISM; PHYSIOLOGY; RAT STRAIN;

AGING; ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; DEOXYGUANOSINE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DNA DAMAGE; GLICLAZIDE; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXIDANTS; OXIDATIVE STRESS; RATS; RATS, INBRED STRAINS; SELEGILINE; SUPEROXIDE DISMUTASE; VITAMIN A; VITAMIN E;

EID: 28844476159     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.1080/07435800500371805     Document Type: Article

References (50)

1. Coppack S. Diabetes mellitus in clinical biochemistry: metabolic and clinical aspects. In: Marshall WJ, Bangert SK, eds. Churchill Livingstone, UK, 1995:257-280.
2. Weiland DA, White RD. Diabetes mellitus. Clin Fam Pract 2002; 4(3):703-752.
3. Diyabet AG, Biyokimyasi I, Onat T, Emerk K, Sözmen E, eds. Carbohydrates. In: Diabetes in Human Biochemistry. Ankara, Palme Yayincilik, 2002:247-253.
4. Poon HF, Calabrese V, Scapagnini V, Butterfield DA. Free radicals and brain aging. Clin Geriatr Med 2004; 20:329-359.
5. Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol 2001; 34:587-592.
6. Saxena AK, Srivastata P, Kale RK, Baquer NZ. Impaired antioxidant status in diabetic rat liver. Effect of vanadate. Biochem Pharmacol 1993; 45(3):539-542.
7. Suciu I, Negrean V, Sampelean D. The oxidative stress in the development of diabetes chronic complications in the elderly. Rom J Intern Med 2004; 42(2):395-406.
8. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/ antioxidant balance. Diabetes Metab 2000; 26:163-176.
9. O'Brien RC, Luo M, Balaz N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabet Complications 2000; 14:201-206.
10. Collins AR, Raslova K, Somorovska M, Petrovska H, Ondrusova A, Vohnout B, Fabry R, Dusinska M. DNA damage in diabetes: correlation with a clinical marker. Free Radic Biol Med 1998; 25:373-377.
11. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339:1-9.
12. Simonson SG, Zhang J, Canada AT, Su Y-F Jr, Benvenist H, Piantadosi CA. Hydrogen peroxide production by monoamine oxidase during ischemia - reperfusion in the rat brain. J Cereb Blood Flow Metab 1993; 13:125-134.
13. Kimoto K, Suzuki K, Kizaki T, Hitomi Y, Ishida H, Katsuta H, Itoh E, Ookawara T, Suzuki K, Honke K, Ohno H. Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003; 303:112-119.
14. Ho E, Bray TM. Antioxidants, NFkappaB activation and diabetogenesis. Proc Soc Exp Biol Med 1999; 222(3):205-213.
15. Rehman A, Nourooz-Zadeh J, Möller W, Tritschler H, Pereira P, Halliwell B. Increased oxidative damage to all DNA bases in patients with type ii diabetes mellitus. FEBS Lett 1999; 448(1):120-122.
16. O'Brien RC, Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism 1997; 146(12, suppl 1):22-25.
17. Prakasam A, Sethupathy S, Pugalendi KV. Effect of casearia esculenta root extract on blood glucose and plasma antioxidant status in streptozotocin diabetic rats. Pol J Pharmacol 2003; 55:43-49.
18. Giugliano D, Paolisso G, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19(3):257-267.
19. Kumar JSS, Menon VP. Effect of diabetes on levels of lipid peroxides and glycolipids in rat brain. Metabolism 1993; 42(11):1435-1439.
20. Sim AS, Salonikas C, Naidoo D, Wilcken DEL. Improved method for plasma malondialdehyde measurement by HPLC using methyl malondialdehyde as an internal standard. J Chromatogr B 2003; 785:337-344.
21. Stevnsner T, Thorslund T, Souza-Pinto NC, Bohr VA. Mitochondrial repair of 8-oxoguanine and changes with aging. Exp Gerontol 2002; 37:1189-1196.
22. Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia 1999; 42:995-998.
23. Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res 1992; 275:331-342.
24. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000; 47:457-464.
25. Torres MD, Canal JR, Perez C. Oxidative stress in normal and diabetic rats. Physiol Res 1999; 48:203-208.
26. Murakami H, Tamasawa N, Matsui J, Yasujima M, Suda T. Plasma oxysterols and tocopherol in patients with diabetes mellitus and hyperlipidemia. Lipids 2000; 35:333-338.
27. Polidori MC. Antioxidant micronutrients in the prevention of age-related diseases. J Postgrad Med 2003; 49:229-235.
28. Adeghate E, Parvez H. The effect of diabetes mellitus on the morphology and physiology of monoamine oxidase in the pancreas. Neurotoxicology 2004; 25:167-173.
29. Alper G, Girgin FK, Ozgönül M, Mentes G, Ersöz B. MAO inhibitors and oxidant stress in aging brain tissue. Eur Neuropsychopharmacol 1999; 9:247-252.
30. 2 toxicity. J Appl Physiol 1991; 71(3):1057-1061.
31. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003; 110:509-515.
32. Carrillo MC, Kanai S, Kitani K, Ivy GO. A high dose of long term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats. Life Sci 2000; 67:2539-2548.
33. Richter C. Oxidative damage to mitochondrial DNA and its relationship to aging. Int J Biochem Cell Biol 1995; 27(7):647-653.
34. Signorini AM, Fondelli C, Renzoni E, Puccetti C, Cragnoli C, Giorgi C. Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus. Curr Ther Res Clin Exp 2002; 63(7):411-420.
35. Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Miyaguchi S, Takahashi K, Toyota T. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metab Clin Exp 1998; 47(8):977-981.
36. Renier G, Mamputu JC, Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 2003; 52(8, suppl 1):13-18.
37. Mamputu JC, Renier G. Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein. Metabolism 2001; 50(6):688-695.
38. Renier GA, Desfaits AC, Serri O. Effect of gliclazide on monocyte-endothelium interactions in diabetes. J Diabet. Complications. 2000; 14:215-223.
39. Henry JB. Diabetes mellitus. clinical diagnosis and mangement by laboratory methods, 20th Ed; In: JB, Henry, ed. WB Saunders: Philadephia, 2001:215.
40. Sözmen EY, Tanyalçin T, Onat T, Kutay F, Erlaçin S. Ethanol induced oxidative stress and membrane injury in rat erythrocytes. Eur J Clin Chem Clin Biochem 1994; 32:741-744.
41. Kraml M. A rapid fluorometric determination of MAO. Biochem Pharmacol 1965; 14:1684-1686.
42. Erel O. A novel automated measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37:277-285.
43. Arnoud J, Fortis I, Blachier S, Kia D, Favier A. A simultaneous determination of retinol, α-tocopherol and β-carotene in serum by isocratic high-performance liquid chromatography. J Chromatogr 1991; 572:103-116.
44. Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, Kukidome D, Wake N, Matsumura T, Miyamura N, Sakakida M, Kishikawa H, Araki E. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003; 26(5):1507-1512.
45. Thomas CE, Huber EW, Ohlweiler DF. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic Biol Med 1997; 22(4):733-737.
46. Kikugawa K, Yasuhara Y, Ando K, Koyama K, Hiramoto K, Suzuki M. Protective effect of supplementation of fish oil with high n-3 polyunsaturated fatty acids against oxidative stress-induced DNA damage of rat liver in vivo. J Agric Food Chem 2003; 51:6073-6079.
47. England T, Beatty E, Regnab A, Nourooz-Zadeh J, Pereira P, O'Reilly J, Wiseman H, Geissler C, Halliwell B. The steady-state levels of oxidative DNA damage and of lipid peroxidation (F2-isoprostanes) are not correlated in healthy human subjects. Free Radical Res 2000; 32:355-362.
48. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 2002; 176:165-173.
49. Sechi LA, Ceriello A, Griffin CA, Catena C, Amstad P, Schambelan M, Bartoli E. Renal antioxidant enzyme mRNA levels are increased in rats with experimental diabetes mellitus. Diabetologia 1997; 40:23-29.
50. Olanow CW. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J Neural Transm Suppl 1996; 48:75-84.